Complete MRD response after cycle 1 by clinical characteristics at baseline and conduct of therapy in cycle 1 (primary end point efficacy set). Three (75%) of 4 patients (95% CI, 19% to 99%) with Ph⁺ ALL and 2 (50%) of 4 patients (95% CI, 7% to 93%) with t(4;11) and/or MLL-AF4⁺ disease had a complete MRD response during cycle 1. MRD complete response rates were similar for patients with or without treatment interruptions during cycle 1. CR1, first CR; CR2/3, second or third CR.